IL17RA and cancer: Although many studies have highlighted that IL-17 and its downstream signaling pathways contribute to poor prognosis in various cancers, including osteosarcoma, NSCLC, gastric cancer, pancreatic carcinoma, and CRC, the impact of IL-17RA on CRC prognosis and progression remains debated.